SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants

被引:7
|
作者
Kubale, John [1 ]
Gleason, Charles [2 ,6 ]
Carreno, Juan Manuel [2 ,6 ]
Srivastava, Komal [2 ,6 ]
Singh, Gagandeep [2 ,6 ]
Gordon, Aubree [1 ]
Krammer, Florian [2 ,5 ,6 ]
Simon, Viviana [2 ,3 ,4 ,5 ,6 ]
机构
[1] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA
[2] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA
[3] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA
[4] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA
[5] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based Med, New York, NY 10029 USA
[6] Icahn Sch Med Mt Sinai, Ctr Vaccine Res & Pandem Preparedness, New York, NY 10029 USA
来源
MBIO | 2022年 / 13卷 / 05期
关键词
SARS-CoV-2; COVID-19; spike-binding antibodies; protection; modeling; antibody durability; COVID-19; RATES;
D O I
10.1128/mbio.01784-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) cohort follows health care workers with and without documented coronavirus disease 2019 (COVID-19) since April 2020. We report our findings regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-binding antibody stability and protection from infection in the pre-variant era. We analyzed data from 400 health care workers (150 seropositive and 250 seronegative at enrollment) for a median of 84 days. The SARS-CoV-2 spike-binding antibody titers were highly variable with antibody levels decreasing over the first 3 months, followed by a relative stabilization. We found that both more advanced age (>40 years) and female sex were associated with higher antibody levels (1.6-fold and 1.4-fold increases, respectively). Only six percent of the initially seropositive participants "seroreverted." We documented a total of 11 new SARS-CoV-2 infections (10 naive participants and 1 previously infected participant without detectable antibodies; P < 0.01), indicating that spike antibodies limit the risk of reinfection. These observations, however, only apply to SARS-CoV-2 variants antigenically similar to the ancestral SARS-CoV-2 ones. In conclusion, SARS-CoV-2 antibody titers mounted upon infection are stable over several months and provide protection from infection with antigenically similar viruses. IMPORTANCE SARS-CoV-2 is the cause of one of the largest noninfluenza pandemics of this century. This exceptional public health crisis highlights the urgent need for better understanding of the correlates of protection from infection and severe COVID-19. We established the PARIS cohort to determine durability and effectiveness of SARS-CoV-2 immune responses. Here, we report on the kinetics of SARS-CoV-2 spike-binding antibody after SARS-CoV-2 infection as well as reinfection rates using data collected between April 2020 and August 2021. We found that antibody levels stabilized at individual steady state levels after an initial decrease with seroreversion being found in only 6% of the convalescent participants. SARS-CoV-2 infections only occurred in participants without detectable spike-binding antibodies, indicating significant protection from reinfection with antigenically similar viruses. Our data indicate the importance of spike-binding antibody titers in protection prior to vaccination and the wide circulation of antigenically diverse variants of concern. SARS-CoV-2 is the cause of one of the largest noninfluenza pandemics of this century. This exceptional public health crisis highlights the urgent need for better understanding of the correlates of protection from infection and severe COVID-19.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] SARS-CoV-2 Reinfection With Different SARS-CoV-2 Variants in Children, Ohio, United States
    Wang, Huanyu
    Wright, Tori
    Everhart, Kathy
    Oyeniran, Sophonie J.
    Mejias, Asuncion
    Leber, Amy L.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2023, 12 (04) : 198 - 204
  • [2] Investigation of SARS-CoV-2 IgG Binding Capability to Variants of the SARS-CoV-2 Virus
    Johnson, Lucy
    De Gascun, Cillian F.
    Hassan, Jaythoon
    VIRAL IMMUNOLOGY, 2024, 37 (08) : 404 - 410
  • [3] Reinfection and reactivation of SARS-CoV-2
    Dowran, Razieh
    Damavandi, Amirmasoud Rayati
    Azad, Talat Mokhtari
    FUTURE VIROLOGY, 2022, : 835 - 844
  • [4] Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
    Clarke, Candice L.
    Prendecki, Maria
    Dhutia, Amrita
    Gan, Jaslyn
    Edwards, Claire
    Prout, Virginia
    Lightstone, Liz
    Parker, Eleanor
    Marchesin, Federica
    Griffith, Megan
    Charif, Rawya
    Pickard, Graham
    Cox, Alison
    McClure, Myra
    Tedder, Richard
    Randell, Paul
    Greathead, Louise
    Guckian, Mary
    McAdoo, Stephen P.
    Kelleher, Peter
    Willicombe, Michelle
    KIDNEY INTERNATIONAL, 2021, 99 (06) : 1470 - 1477
  • [5] Infectivity of SARS-CoV-2 and protection against reinfection in rats
    Yu, Dandan
    Long, Yanghaopeng
    Xu, Ling
    Han, Jian-Bao
    Xi, Jiawei
    Xu, Jianlin
    Yang, Lu-Xiu
    Feng, Xiao-Li
    Zou, Qing-Cui
    Qu, Wang
    Lin, Jiangwei
    Li, Ming-Hua
    Yao, Yong-Gang
    ZOOLOGICAL RESEARCH, 2022, 43 (06) : 945 - 948
  • [6] Relationship between Antibody Levels and SARS-Cov-2 Reinfection
    Islamoglu, Mehmet Sami
    Cengiz, Mahir
    Uysal, Betul Borku
    Ikitimur, Hande
    Ozdemir, Zeynep
    Karamehmetoglu, Ahsen
    Akbulut, Ayse Ezgi
    Bakdur, Ayse Nur
    Ozdemir, Azize
    Kayikcioglu, Habibe
    Ozdemir, Hatice
    Uces, Rumeysa
    Ersoy, Sema
    Yavuzer, Serap
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2021, 51 (06): : 750 - 755
  • [7] MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus
    DeBarros, Kenya
    Khan, Mahfuz
    Coleman, Morgan
    Bond, Vincent C.
    Floyd, Virginia
    Gbodossou, Erick
    Diop, Amad
    Krumpe, Lauren R. H.
    O'Keefe, Barry R.
    Powell, Michael D.
    VIRUSES-BASEL, 2024, 16 (09):
  • [8] A case with SARS-CoV-2 reinfection from India
    Munivenkatappa, Ashok
    Sahay, Rima R.
    Deshpande, Gururaj R.
    Patil, Deepak Y.
    Shete, Anita M.
    Sapkal, Gajanan N.
    Kumar, Ravish
    Narayana, Marappa
    Yadav, Pragya D.
    Shettar, Vijay
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2022, 40 (01) : 166 - 168
  • [9] Reinfection With SARS-CoV-2: Implications for Vaccines
    Cohen, Jeffrey, I
    Burbelo, Peter D.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E4223 - E4228
  • [10] Epidemiological assessment of SARS-CoV-2 reinfection
    Almadhi, Marwa
    Alsayyad, Adel Salman
    Conroy, Ronan
    Atkin, Stephen
    Al Awadhi, Abdulla
    Al-Tawfiq, Jaffar A.
    AlQahtani, Manaf
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 123 : 9 - 16